Cabometyx in combination with Opdivo provides efficacy benefits regardless of prior nephrectomy in patients with previously untreated advanced RCC

The cancer center program of the NCI is a success that is admired not only within the NIH but worldwide. This is due, in large part, to the cancer center review process that has evolved and strengthened over the years.

May 09, 2025

Vol.51 No.18

By George J. Weiner

Regulatory News

Cyber-iconoclast Vinay Prasad named head of FDA’s CBER
An oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies

Vinay Prasad, a MAHA-aligned hematologist-oncologist with an avid cyber following, was named director of the FDA Center for Biologics Evaluation and Research, where he will be responsible for the agency’s regulation of vaccines and biologics, including cell and gene therapies.

May 09, 2025

Vol.51 No.18

By Claire Marie Porter

Clinical Trials & Tribulations

Working with cancer: Rethinking long-term health for working-age adult cancer survivors

As the number of cancer survivors in the U.S. continues to rise and the age at diagnosis for some cancers appears to be shifting younger, the need for long-term survivorship care is more urgent than ever.

May 09, 2025

Vol.51 No.18

By Susan A. Speckhart, Rebecca Miksad and Lidia Schapira

Rewriting the rules of cancer treatment one nanobody at a time

I joined Translational Genomics Research Institute, part of City of Hope, late last year to launch the Center for Accelerated Nanotherapeutics.

May 09, 2025

Vol.51 No.18

By John D. Fryer

Cabometyx in combination with Opdivo provides efficacy benefits regardless of prior nephrectomy in patients with previously untreated advanced RCC

YOU MAY BE INTERESTED IN

In the Headlines: “There’s no one to stand up for NCI right now.”

Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit

George Weiner: Cancer centers are special, as are site visits in CCSG review

Cyber-iconoclast Vinay Prasad named head of FDA’s CBER
An oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies

Working with cancer: Rethinking long-term health for working-age adult cancer survivors

Rewriting the rules of cancer treatment one nanobody at a time

Renew today!

Subscriber content

Never miss an issue!

Login

Cabometyx in combination with Opdivo provides efficacy benefits regardless of prior nephrectomy in patients with previously untreated advanced RCC

YOU MAY BE INTERESTED IN

In the Headlines: “There’s no one to stand up for NCI right now.”

Trump administration is removing the mainstays of NCI and the federal government’s cancer programPeer review, registries, and evidence-based patient information take a big hit

George Weiner: Cancer centers are special, as are site visits in CCSG review

Cyber-iconoclast Vinay Prasad named head of FDA’s CBERAn oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies

Working with cancer: Rethinking long-term health for working-age adult cancer survivors

Rewriting the rules of cancer treatment one nanobody at a time

Never miss an issue!

Login

Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit

Cyber-iconoclast Vinay Prasad named head of FDA’s CBER
An oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies